Keeping Track: Approvals Aplenty As FDA Clears Taltz, Cinqair And Anthim
The latest drug development news and highlights from our FDA Performance Tracker.
You may also be interested in...
The latest drug development news and highlights from our FDA Performance Tracker
Ixekizumab had a smooth FDA approval, with no advisory committee needed for the second member of the IL-17 inhibitor class.
In remarks fleshing out the ‘EUA Plus’ guidance before it became a political football, Operation Warp Speed’s Slaoui said that an FDA analysis concluded that 90% of adverse events related to vaccination take place within the first 42 days.